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CHARACTERIZATION OF THE RECRUITMENT OF INTIMAL SMOOTH 
MUSCLE CELLS IN VASCULAR DISEASE 
 
 
SUNYOUNG JANG 
 
 
ABSTRACT 
 
Intimal hyperplasia occurs as a response to a variety of vascular insults and results 
in vascular stenosis, and organ ischemia. This process represents a fundamental 
component of atherosclerosis, venous graft stenonsis, and allograft arteriopathy in solid 
organ transplants. Smooth muscle cells (SMCs), and their associated extracellular matrix 
(ECM) form major components of intimal hyperplasia. We hypothesize that chemokines 
play a critical role in SMC migration into such intimal lesions. A number of chemokine-
chemokine receptor interactions that mediate inflammatory cell recruitment have been 
characterized. However, the specific chemokine- chemokine receptor pathways that 
contribute to SMC recruitment are not known. The aims of this study are to examine the 
expression of C-C chemokine receptor 1 (CCR1) on medial SMCs (MSMCs), and to test 
its functionality in SMC recruitment. SMCs were derived from murine aortas; cultures 
were >95% SMC as demonstrated by the expression of smooth muscle α-actin (SMA), 
calponin, smooth muscle myosin heavy chain (SM-MHC). Interferon-gamma (IFN-γ) and 
Tumor necrosis factor- alpha (TNF-α) – stimulated MSMCs express CCR1 with a peak 
expression between 30 h and 48 h after cytokine stimulation. The functionality of 
receptors was initially demonstrated by agonist-induced calcium mobilization: the 
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addition of CCR1 ligands, Regulated on activation, Normal T cell expressed and secreted 
(RANTES) and Macrophage inflammatory protein -1α (MIP-1α) to MSMCs caused an 
increase in intracellular Ca2+ concentration. Blockade of CCR1 by BX471, a CCR1 
antagonist, inhibited the Ca2+ mobilization induced by RANTES and MIP-1α. The results 
suggest that up-regulation of CCR1 expression on cytokine-stimulated SMCs may 
facilitate recruitment into intimal lesions through endothelial-derived chemokine 
expression. 
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INTRODUCTION 
 
 
Intimal hyperplasia, which occurs in response to vascular injury, represents a 
fundamental component of vasculoproliferative disorders such as atherosclerosis, venous 
graft stenonsis, and allograft arteriopathy in solid organ transplants12. Smooth muscle 
cells (SMCs), and their associated extracellular matrix (ECM) are major components of 
intimal hyperplasia15, 16.  We hypothesized that chemokines play a critical role in SMC 
migration into such intimal lesions. A number of chemokine-chemokine receptor 
interactions have been characterized for inflammatory cell recruitment1, 2. However, the 
specific chemokine-chemokine receptor pathways that contribute to SMC recruitment are 
not known. 
The earliest response to vascular injury takes place within the endothelium, 
resulting in endothelial dysfunction12. Endothelial cell (EC) injury promotes adhesion 
molecule expression, which in turn increases the attachment and activation of circulating 
inflammatory cells. A variety of recruited cell types, including activated ECs, platelets, 
inflammatory cells, and SMCs subsequently secrete inflammatory mediators, such as 
cytokines and growth factors that drive lesion progression12. Although the exact 
molecular mechanisms are incompletely defined, inflammatory events cause SMC 
activation and proliferation within the intima, and the expanded intima subsequently 
leads to vascular occlusion.  
SMCs are the most abundant cell type in a normal vessel and also are the major 
cellular constituent in intimal hyperplastic lesions. Notably, a number of studies have 
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shown phenotypic differences between MSMCs and those found within intimal lesions1, 
20, 22
. MSMCs exhibit a non-proliferative, non-synthetic, and contractile phenotype, 
whereas intimal SMCs (iSMCs) are less-differentiated with non-contractile, proliferative, 
and synthetic characteristics. Contractile MSMCs regulate vascular tone, blood pressure, 
and lumen size, and generally produce relatively little ECM.  In response to injury, these 
SMCs undergo a phenotypic switch from the contractile phenotype to the active, 
synthetic phenotype. In this state, iSMCs proliferate and migrate to the intima where 
markedly increase ECM synthesis1, 20, 22. However, although iSMCs share some 
similarities with MSMCs, definitive evidence of phenotypic interconversion is lacking. In 
addition, the distinct functional differences suggest that MSMCs may have a different 
cell of origin than intimal SMCs9, 11.  
Given the functional and phenotypic differences between MSMCs and iSMCs, the 
source of SMCs in intimal lesions has been subject of considerable research. It was 
initially hypothesized that mSMCs migrate from the media into the intima, where they 
subsequently proliferate and synthesize ECM20. However, more recent studies suggest 
that other sources of iSMCs may exist, including bone marrow-derived cells10, 13. A 
growing body of evidence supports the notion that SMCs in intimal lesions derive from 
multiple sources, and that bone marrow precursors account for up to 10-15% of the total 
of intimal SMC population13.  
The recruitment of SMCs to the intima is an essential step in most 
vasculoproliferative disorders.  We hypothesized that the migratory and proliferative 
activities of SMCs are regulated through the interactions of chemokines with their 
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corresponding receptors. Chemokines are small proteins which play a critical role in 
inflammatory events by regulating inflammatory cell trafficking and inducing the 
activation and migration of smooth muscle cells to site of vascular injury21, 23, 25. 
Chemokines can be classified into four subfamilies based on the number and the 
arrangement of conserved cysteine residues: C, CC, CXC, and C(X)3C. The cellular 
effects of chemokines are mediated through binding to specific seven transmembrane-G-
protein-coupled receptors29. Table 1 lists a summary of the major chemokines and their 
associated receptors that are potentially involved in SMC recruitment and activation.  
Multiple chemokines can bind to CCR1, CCR2, or CXCR3 receptors, and are 
expressed at high levels in intimal lesions16. Modulation of such chemokines or blockade 
of their receptors can ameliorate intimal hyperplasia14. An elegant study by Shimizu et al. 
suggested that MSMCs and iSMCs have distinct chemokine receptor expression, and that 
MSMCs do not express chemokine receptors that facilitate intimal recruitment. Moreover, 
the authors of this study demonstrated that stimulation of CCR1 by its ligand, RANTES, 
specifically promotes iSMCs proliferation.  In addition, they showed that intimal 
hyperplasia was attenuated in CCR1-deficient animal models11. We hypothesized that EC 
are a potential source of the chemokines responsible for the activation and recruitment of 
these MSMCs. The specific chemokine-chemokine receptor pathways that regulate 
MSMC recruitment remain unclear. We tested our hypothesis by treating quiescent 
MSMCs with the pro-inflammatory cytokines, IFN-γ and TNF-α to mimic vascular injury 
and then evaluated whether these cytokines can activate and modulate the phenotypic 
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switch in MSMCs and eventually induce migration and proliferation through the CCR1-
regulated pathway.  
The aim of this study was to examine the capacity of MSMCs to express relevant 
chemokine receptors. We specifically investigated the expression of CCR1 in MSMCs, 
comparing CCR1 expression in the presence and absence of IFN-γ and TNF-α. We also 
verified that CCR1 expression was functional by evaluating responsiveness to CCR1 
ligands. To assess the functionality of CCR1 to its corresponding chemokine, we tested 
the effect of RANTES and MIP-1α on MSMC function. Our results suggest that MSMCs 
can up-regulate the expression of functional CCR1 after cytokine stimulation.  
 
 
 
 
 
 
Table 1. Chemokine receptors and their cognate ligands potentially involved in SMC 
activation and recruitment 
Chemokine Receptors      Ligands 
CXC receptors (CXCR1 to CXCR6) 
CXCR3       Mig, IP-10, I-TAC 
CXCR4       SDF-1α, 1β; PBSF 
 
CC receptors (CCR1 to CCR11) 
CCR1        MIP-1α, RANTES, MCP-1 
CCR2        MCP-1, MCP-2, MCP-3,  
        MCP-4, HCC4 
CCR3        Eotaxin, Eotaxin-2, MCP-3, 
        RANTES, MCP-2, MCP-4 
CCR4        TARC, MDC 
CCR5        MIP-1α, 1β; RANTES, 
        Eotaxin, HCC1, HCC4 
       Adapted from Mitchell et al., 2007  
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MATERIALS & METHODS 
 
 
2.1 Mice 
 
 C57BL/6 mice (8 weeks) were purchased from The Charles River Laboratories 
(Wilmington, MA). 
 
2.2 Reagents 
 
 Recombinant mouse interferon gamma (IFN-γ), Recombinant mouse tumor 
necrosis factor alpha (TNF-α), and Monoclonal antibody (mAB) to CCR1 were 
purchased from R&D systems (Minneapolis, MN).  Monoclonal rat anti- mouse CD31-
Phycoerythrin (PE) antibody was purchased from BD biosciences (San Jose, California). 
Recombinant RANTES (CCL5), MIP-1α (CCL3), and Recombinant rat platelet-derived 
growth factor (PDGF) – BB were purchased from R&D systems (Minneapolis, MN). 
Fluo-4-AM was purchased from Life Technologies (Carlsbad, CA) and Ionomycin, 
BX471(R-N-[5-chloro-2-[2-[4-[(4-fluorophenyl) methyl] - 2-methyl-1-piperazinyl]-2-
oxoethoxy] phenyl] urea hydrochloric acid salt), and Monoclonal anti-α smooth muscle-
FITC was purchased from Sigma-Aldrich (St. Louis, MO). Anti-calponin antibody and 
Anti-myosin smooth muscle heavy chain 1 and 2 antibody were purchased from Abcam 
(Cambridge, MA). 
 
2.3 Primary smooth muscle cells (SMC) isolation and culture 
   
Aortas were harvested from 8 week- old WT B6 mice with sterile dissecting 
scissors. Adipose tissue was carefully removed, and aortas were placed in a 60-mm Petri 
dish containing Dulbecco’s modified eagle medium (DMEM) with 5mg/ml Collagenase 
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type II and incubated for 20 minutes at 37ºC, before being placed in cold DMEM to 
remove adventitia. The aortas were then transferred to Collagenase type I and Elastase 
type III mixture in a 10 cm Petri dish, cut into pieces and incubate for 30 to 40 minutes at 
37ºC for a second round of digestion. Digested tissues and medium were transferred to 
fresh SMC culture medium (DMEM with 5% FBS, 1% penicillin/streptomycin; 2% non-
essential amino acids, 1% L-glutamine; Life Technologies) and plated in a T75 flask 
(Corning, Fisher scientific) and grown at 37ºC. The purity of SMC cultures was >95%, 
as determined by flow cytometry with anti-SM α-actin(SMA), calponin, and smooth 
muscle myosin heavy chain (SM-MHC)  antibodies. SMCs of passages 4 to 13 were used 
for the study. 
 
2.4 Flow cytometry analysis 
 
For quantitative analysis of CCR1 expression on the cell surface, C57bl6 medial 
smooth muscle cells were cultured in medium alone or in the presence of recombinant 
mouse IFN-γ ( 10ng/ml; R&D Systems) and TNF-α (10ng/ml; R&D Systems) for 48 
hours at 37ºC. Cells were then harvested with trypsin (0.25% trypsin-EDTA; Invitrogen) 
for one minute at 37ºC and then washed with SMC culture medium (DMEM with 5% 
FBS, 1% penicillin/streptomycin; 2% non-essential amino acids, 1% L-glutamine; 
Invitrogen). Cells were then washed once with 1% fetal bovine serum (FBS) in Phosphate 
buffered saline (PBS) and incubated with Allophycocyanin (APC) -conjugated anti-
CCR1 (R&D Systems) or control isotype (rat IgG2A; BD Biosciences) on ice for 30 
minutes; after washing in 1% fetal bovine serum in PBS, cells were analyzed by flow 
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cytometer (FACScalibur, BD Biosciences, San Jose, CA), and the data were collected ( 
logarithmic scale) and expressed as the percentage of positive cells. The fluorescence 
produced by isotype-matched control antibody was considered background. 
 
2.5 Immunofluorescence of CCR1 in medial smooth muscle cells 
 
 C57BL/6 medial smooth muscle cells were cultured under adherent conditions in 
12-well plates in the presence of recombinant mouse IFN-γ (10ng/ml; R&D Systems) and 
TNF-α (10ng/ml; R&D Systems) for 48 hours at 37ºC. Cells were then washed once with 
1% fetal bovine serum in PBS, and then incubated for 30 min on ice with either a mAB 
anti- mouse CCR1 (R&D Systems) or the control isotype antibody (BD biosciences) at 
1:100 dilution in 1% fetal bovine serum in PBS. After a final wash, cells were imaged on 
an Olympus microscope and analyzed using MetaMorph software (Molecular Devices 
Corp). 
 
2.6 Intracellular Ca2+ influx measurement 
 
 For calcium measurements, C57bl6 medial smooth muscle cells were cultured in 
medium alone or stimulated with recombinant mouse IFN-γ (10 ng/ml) and TNF-α (10 
ng/ml) for 48 hours at 37ºC, then trypsinized and resuspended in pre-warmed (37ºC) 
Hanks’ balanced salt solution (HBSS) containing the calcium-sensitive dye Fluo-4 AM 
ester (2 µM, Life technologies). The cell suspension was then incubated at 37ºC for 15 
minutes. After washing twice in HBSS, Fluo-4-loaded cells were equilibrated at room 
temperature for one hour. Intracellular free Ca2+ was first recorded for 30 seconds to 
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establish a baseline. The cells were then stimulated by adding Ionophore (2 µM; A23187; 
Sigma-Aldrich), MIP-1α (100 ng/ml; R&D Systems), or RANTES (100 ng/ml; R&D 
Systems). After stimulation with different agonists, cells were screened continuously in a 
FACScan for 2 minutes to assess the increase in mean fluorescence induced by each 
agonists and were related to the fluorescence obtained by baseline. For the CCR1 
blocking experiment, medial SMCs were treated with BX471 (250 nM, Sigma Aldrich), a 
CCR1 antagonist, for 15 minutes before the addition of agonists. The effect of the Ca2+ 
ionophore (A23187, Life technologies) and PDGF-B (R&D System) were used as 
positive controls for Ca2+ flux.  
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RESULTS 
 
 
3.1 MSMCs express typical SMC markers 
 
 MSMCs were derived from uninjured aortas and cultures were first analyzed for 
typical SMC markers. Previously proven markers used for SMC lineage indications are: 
a) α-SMA (smooth muscle α-actin), an actin isoform typical of SMC and constitutive 
elements in SMC;7 b) calponin, a calcium-binding protein that normally functions to 
inhibit SMC contraction;8 and c) SM-MHC (smooth muscle myosin heavy chain), a 
myosin contractile protein specific for the SMC lineage.4 At confluence, MSMCs were 
harvested; fixed and permeabilized, then stained with typical SMC markers indicated 
above. Flow cytometry analysis showed high expression levels of all markers in MSMCs, 
although SM-MHC was expressed in MSMCs to a lesser extent than for the other two 
markers (Fig 1B-D). Furthermore, the purity of MSMCs was evaluated by staining for 
cell surface expression of endothelial cell-specific marker, platelet endothelial cell 
adhesion molecule (PECAM-1, also known as CD31). Flow cytometry analysis showed 
that the MSMCs were simultaneously negative for CD31, which excludes endothelial 
cells contamination (Fig 1F). 
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Figure 1.  Flow cytometry analysis of specific SMC markers on MSMCs.  A. Forward 
(size) vs. side (granularity) scatter and the enclosed area was the population analyzed in 
B, C, and D. The smaller cells in the lowest forward (FSC) and side scatter (SSC) 
represent dead cells which were excluded from analysis. B-D. The histograms show the 
relative fluorescence intensity of the MSMCs stained with specific SMC markers, 
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including SMA, calponin, and SM-MHC11 (blue line). The red line represents the 
isotype-matched control antibody. MSMCs are positive for SMA (A), calponin (B) and 
SM-MHC11 (C). E-F. Purity of MSMCs, as measured by CD31-negative cells. E. Cells 
were gated on FSC and SSC to exclude dead cells. F. The additional histogram for 
MSMCs shows the negative CD31 expression (F, orange line) compared to the positive 
control (F, blue line). The red line (F) indicates staining with isotype-matched control 
antibody. 
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3.2 Expression of CCR1 on MSMCs. 
 
 We performed flow cytometry analysis to characterize the effects of the addition 
of both IFN-γ (10 ng/ml) and TNF-α (10ng/ml) on MSMCs surface expression of CCR1. 
At confluence, cells were cultured in the absence of cytokines or in the presence of 
cytokines for 48h at 37ºC. Cells were then examined to determine the percentage of cells 
that expressed CCR1, as well as the mean fluorescence intensity of this expression. Flow 
cytometry analysis revealed that addition of both IFN-γ (10 ng/ml) and TNF-α (10 ng/ml) 
caused higher mean fluorescence intensity of CCR1 expression (Fig 2C) than in the 
absence of cytokines (Fig 2B). In Fig 2, an APC-labeled Ab against CCR1 was used. 
CCR1 expression on MSMCs was further analyzed by immunofluorescent staining. 
Immnuofluorescence showed that cytokine-stimulated MSMCs displayed a high 
percentage of cells stained positive for CCR1 (Fig 2E), confirming the previous results 
obtained by flow cytometry.  
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Figure 2. Flow cytometry analysis of CCR1 expression by unstimulated and 
cytokine-stimulated MSMCs. A. MSMCs were gated on FSC and SSC to exclude dead 
cells. B-C. The histograms show the relative fluorescence intensity of the cells stained 
with anti-CCR1 antibody (blue line) compared with the corresponding isotype control 
(red line). Confluent MSMCs (passages 4-13) were cultured in the absence of cytokines 
(B) or in the presence of cytokines for 48 hours (C) and analyzed by flow cytometry for 
cell surface expression of CCR1. Higher CCR1 expression is seen on cytokine-stimulated 
MSMCs (C) than for unstimulated cells (B).  
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D.  
 
 
 
E. 
 
 
 
Figure 2D-E. Immunofluorescent staining of CCR1 in MSMCs.  Immuonofluorescent 
analysis of CCR1 (red) expression in MSMCs. MSMCs were stimulated with or without 
IFN-γ (10 ng/ml) and TNF-α (10ng/ml). Cytokine-stimulated MSMCs showed a higher 
percentage of cells stained positive for CCR1 (E) than for unstimulated cells (D). 
Magnification is 20X. 
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3.3 CCR1 expression increases at 30 h and 48 h 
 In order to characterize the time course of maximal CCR1 expression, CCR1 
expression on the cell surface was also determined during a longer time course. Time 
course analysis of CCR1 expression was determined 6, 12, 18, 24, 30, 36, 42, and 48 
hours following treatment of MSMCs with both IFN-γ (10ng/ml) and TNF-α (10ng/ml). 
The percentage of CCR1 expressing cells, defined as CCR1- positive cells, showed peak 
expression at 30 h to 48 h after treatment (Fig 3). 
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Figure 3. Time course analysis of CCR1 surface expression on MSMCs.  A. MSMCs 
were gated on FSC and SSC to exclude dead cells. B. Cytokine- stimulated MSMCs were 
stained with anti-CCR1-APC after the indicated time in culture. IFN-γ and TNF-α –
stimulated MSMCs express CCR1 with a peak expression between 30 h and 48 h after 
cytokine stimulation. 
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3.4 Addition of RANTES and MIP-1α induce calcium mobilization in MSMCs 
  
 Receptor expression alone does not prove functionality. Chemokine binding to 
chemokine receptors should induce several intracellular changes, including mobilization 
of intracellular calcium21. Therefore calcium mobilization studies were performed to 
further characterize whether the chemokine receptor expressed on MSMCs was 
functionally active. MSMCs were stimulated with cytokines for 48 h at 37ºC, and then 
allowed to take up Fluo-4 (2 µM) at 37ºC for 10 min. These cells were then treated with 
100ng/ml MIP-1α or RANTES. Treatment of cytokine-stimulated MSMCs with 
RANTES (Fig 4D) and MIP-1α (Fig 4E) caused an increase in intracellular Ca2+ 
concentration. To establish the maximal Ca2+ flux, MSMCs were stimulated with 2 µM 
ionophore (Fig B). Platelet-derived growth factor-B (PDGF at 50 ng/ml; Fig C) was used 
as a positive control. The FACS analysis indicated that the CCR1 expressed in MSMCs 
was functional based on response to ligands, RANTES and MIP-1α. 
 In addition, we examined whether the induction of Ca2+ mobilization by RANTES 
and MIP-1α occurred through CCR1. Anders et al. demonstrated that blockade of CCR1 
by BX471, a CCR1 antagonist, reduced leukocyte infiltration and renal fibrosis after 
unilateral ureter obstruction (UUO)16. Therefore, Fluo-4 preloaded MSMCs were treated 
with BX471 (250nM) to test its ability to inhibit agonist-induced Ca2+ mobilization in 
CCR1 expressing MSMCs. Preliminary data showed that BX471 inhibited Ca2+ 
mobilization induced by RANTES (Fig 4G) and MIP-1α (Fig 4H), demonstrating that 
BX471 is a CCR1 specific antagonist. When administered alone, BX471 did not induce 
Ca2+ mobilization, indicating that it has no internal agonistic activity (Fig 4F). 
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Figure 4. Measurement of Ca2+ in cultured MSMCs in response to MIP-1α and 
RANTES.  A. Forward (size) vs. side (granularity) scatter and the enclosed area was the 
population analyzed in B, C, D, and E. B-E. The effect of different agonists on 
intracellular Ca2+ concentration in Fluo-4 preloaded MSMCs was studied by flow 
cytometry. Cytokine-stimulated MSMCs were treated with either RANTES (100 ng/ml) 
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or MIP-1α (100 ng/ml), and intracellular Ca2+ was measured for at least 2 minutes. 
Ionophore (2 µM) and PDGF-B (50 ng/ml) were used as positive controls. RANTES (D) 
and MIP-1α (E) induced Ca2+ mobilization in MSMCs as well as the positive controls, 
ionophore (A) and PDGF-B (B). F-H Fluo-4 preloaded MSMCs were pretreated with 
BX471 for 15 minutes then treated with CCR1 chemokines, MIP-1α (100 ng/ml) and 
RANTES (100 ng/ml). BX471 inhibited the ability of CCR1 chemokines, RANTES (G) 
and MIP-1 α (H) to increase intracellular Ca2+ concentration. BX471 alone did not induce 
Ca2+ mobilization (F). Data are shown as representative experiment (n=1). 
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DISCUSSION 
 
 Intimal hyperplasia in response to vascular insults is the fundamental pathological 
event in most vascular diseases12. SMC and BM-derived cells can migrate into vessel 
intima following injury, resulting in vascular stenosis13,20.  The specific chemokines that 
coordinate these events and the molecular mechanisms that underlie the recruitment of 
SMCs to the intima are largely unknown. In this study, we aimed to identify chemokine 
receptors on MSMCs that are induced by inflammatory stimuli to drive their recruitment 
to intima.  
Using primary MSMCs cultures from uninjured aortas, the key findings of this 
study include: a) MSMCs can be cultured at >95% homogeneity as determined by SMC 
marker expression; b) pro-inflammatory cytokines, IFN-γ and TNF-α, significantly up-
regulate CCR1 expression on MSMCs as shown by flow cytometry; c) among the known 
CCR1 chemokines, RANTES and MIP-1α cause an increase in intracellular Ca2+ on 
cytokine-stimulated SMCs, suggesting that CCR1 expressed on MSMCs in response to 
IFN-γ and TNF-α is functional; and d) blockade of CCR1 by BX471 abolished the ability 
of RANTES and MIP-1α to induce Ca2+ mobilization. Taken together, the results suggest 
that functional CCR1 is expressed on cytokine-stimulated MSMCs. 
   The markers that are used to identify SMCs are well established10. MSMC 
cultures derived from uninjured aortas were >95% SMC as demonstrated by specific 
SMC markers, including α-SMA, and calponin, although SM-MHC was expressed in 
MSMCs to a lesser extent than the other two markers. To investigate whether CCR1 is 
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expressed on MSMCs, we stimulated MSMCs with IFN-γ and TNF-α; these two pro-
inflammatory cytokines were found to effectively induce CCR1 expression on cultured 
MSMCs.  
 Chemokines are important chemoattractant that regulate inflammatory cell 
trafficking and promote SMC migration and proliferation21, 23, 25. Previous studies 
demonstrated that a high level of chemokines including RANTES, MCP-1 (Monocyte 
chemotactic protein-1), MIP-1α, IP-10 (Interferon gamma-induced protein 10), and I-
TAC (Interferon-inducible T cell-chemoattractant) are present in intimal lesions and 
could conceivably regulate SMC recruitment to the intima11. Shimizu et al. found that 
RANTES served as a chemoattractant to direct iSMC migration and proliferation in 
intimal lesions through the activation of CCR1. RANTES can be produced by activated 
ECs, T cells, macrophages, and platelets11. In order to investigate whether CCR1 
expression on MSMCs was functional, an agonist-induced Ca2+ mobilization assay was 
performed. Preliminary data demonstrated that both RANTES and MIP-1α caused 
increases in intracellular Ca2+ concentration. This signaling was abrogated by BX471 
(CCR1 antagonist) blockade; our results, not yet confirmed, showed that BX471 inhibited 
Ca2+ mobilization induced by RANTES and MIP-1α. Experiments are under way to 
demonstrate that the RANTES and MIP-1α (CCR1 ligands) are responsible for the Ca2+ 
mobilization. Additional data (not shown) demonstrated that cytokine-stimulated 
MSMCs, also exhibited increased chemotaxis to stable gradients of cultured supernatants 
from activated endothelial cells. The preliminary data suggests that cytokine-stimulated 
SMCs may be induced to migrate via a CCR1-regulated pathway.  
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 Shimizu et al. examined the expression of CCR1 on both MSMCs and iSMCs and 
reported it to be absent on activated MSMCs11. A possible explanation of this apparently 
discrepant result is that the number of passages or the cellular confluence at the time of 
testing was different. Our work shows that the cellular density has a significant effect on 
the CCR1 expression in the setting of IFN-γ and TNF-α stimulation. In addition, Shimizu 
et al. stimulated MSMCs with IFN-γ and TNF-α for only 24 hours. However, our 
timecourse study revealed that peak expression of CCR1 in MSMCs -stimulated with 
cytokines occurs between 30 h and 48 h (Fig 3).  
 Although CCR1 expression was present on nearly all cytokine-stimulated 
MSMCs, mobilization of intracellular calcium after ligand binding (RANTES and MIP-
1α), was restricted to a subpopulation in MSMCs (Fig 4A), likely reflecting cell viability. 
We hypothesize that in addition to CCR1 expression, cytokine stimulation of MSMC 
induces a pro-apoptotic state. If these activated MSMCs do not bind to CCR1 ligands, 
they undergo a programmed cell death. Consequently, the CCR1 expression level and 
binding of RANTES and MIP-1α to CCR1 do not correlate with calcium flux.  
 Our results suggest that MSMCs can be stimulated to express the chemokine 
receptors, CCR1. This up-regulation of functional CCR1 expression on cytokine-
stimulated MSMCs may facilitate recruitment into intimal lesions. Further work will be 
required to demonstrate chemotaxis on activated MSMCs to stable gradients of CCR1 
ligands. In addition, siRNA knock down of selected endothelial-derived chemokines will 
allow the identification of the relevant mediators. 
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